TG Therapeutics, Inc. (NASDAQ:TGTX) Shares Acquired by Tower Research Capital LLC TRC

Tower Research Capital LLC TRC raised its holdings in shares of TG Therapeutics, Inc. (NASDAQ:TGTX - Free Report) by 937.6% in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 32,498 shares of the biopharmaceutical company's stock after buying an additional 29,366 shares during the quarter. Tower Research Capital LLC TRC's holdings in TG Therapeutics were worth $978,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors have also modified their holdings of the stock. Bleakley Financial Group LLC acquired a new position in TG Therapeutics in the fourth quarter worth about $245,000. Castellan Group bought a new stake in TG Therapeutics in the fourth quarter valued at $8,539,000. Barclays PLC increased its position in shares of TG Therapeutics by 83.9% during the 3rd quarter. Barclays PLC now owns 347,057 shares of the biopharmaceutical company's stock worth $8,117,000 after purchasing an additional 158,323 shares in the last quarter. JPMorgan Chase & Co. boosted its position in TG Therapeutics by 60.0% in the third quarter. JPMorgan Chase & Co. now owns 720,798 shares of the biopharmaceutical company's stock valued at $16,859,000 after buying an additional 270,286 shares in the last quarter. Finally, Stratos Wealth Advisors LLC acquired a new stake in shares of TG Therapeutics during the fourth quarter worth approximately $241,000. Institutional investors and hedge funds own 58.58% of the company's stock.

Analyst Upgrades and Downgrades

TGTX has been the subject of several research reports. HC Wainwright restated a "buy" rating and issued a $55.00 price objective on shares of TG Therapeutics in a research report on Tuesday, March 4th. StockNews.com upgraded TG Therapeutics from a "sell" rating to a "hold" rating in a report on Tuesday, March 4th. Two research analysts have rated the stock with a hold rating and five have assigned a buy rating to the stock. According to MarketBeat.com, TG Therapeutics has a consensus rating of "Moderate Buy" and an average target price of $40.67.

TG Therapeutics Price Performance

TG Therapeutics stock traded up $0.40 during midday trading on Thursday, hitting $45.91. 1,272,443 shares of the company's stock were exchanged, compared to its average volume of 2,684,631. The company has a debt-to-equity ratio of 1.27, a quick ratio of 3.91 and a current ratio of 4.59. The stock has a 50-day moving average price of $37.95 and a two-hundred day moving average price of $32.90. TG Therapeutics, Inc. has a 52-week low of $15.16 and a 52-week high of $46.40. The company has a market cap of $7.29 billion, a P/E ratio of -459.07 and a beta of 2.14.

TG Therapeutics (NASDAQ:TGTX - Get Free Report) last announced its quarterly earnings results on Monday, March 3rd. The biopharmaceutical company reported $0.15 EPS for the quarter, topping analysts' consensus estimates of $0.08 by $0.07. TG Therapeutics had a negative return on equity of 8.32% and a negative net margin of 5.42%. The company had revenue of $108.19 million during the quarter, compared to analyst estimates of $100.67 million. On average, equities research analysts forecast that TG Therapeutics, Inc. will post 0.08 earnings per share for the current year.

TG Therapeutics Profile

TG Therapeutics, Inc, a commercial stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases in the United States and internationally. It provides BRIUMVI, an anti-CD20 monoclonal antibody for the treatment of adult patients with relapsing forms of multiple sclerosis (RMS), including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease in adults.